| Revenue growth | 38% YoY growth in Q1FY27. |
|---|---|
| Margins | EBITDA margin improved to 29% from 24% YoY. |
| Order book | 65+ oncology contracts executed; 50+ commercial discussions underway. |
| Demand visibility | Strong demand across countries and new market authorizations. |
| Management confidence | High; citing oncology momentum and expanding market share. |
Growth
Revenue reached ₹7,297 lakhs (+38% YoY); EBITDA at ₹2,125 lakhs (+67% YoY); PAT at ₹1,028 lakhs (+120% YoY).
Outlook
Targeting 100+ overseas contracts and 300+ dossier approvals in 2 years; transitioning to high-margin oncology-led value creation.
Risks
Exposed to global economic performance, international competition, and stringent regulatory requirements for oncology dossiers.
Last quarter's promises, checked
Delivered
- Guided 40% growth for FY26 → delivered 42% (= BEAT)
- Guided EBITDA margin 25-30% → delivered 29% (= BEAT)
- Guided 125 oncology dossiers filed → delivered 178 (= BEAT)
Partly delivered
- Guided 100+ overseas contracts → delivered 65+ (= PARTIAL)
Investor Presentation filed with NSE, NSE: SAKAR. Summary written with AI assistance from the document.
Sakar Healthcare Ltd: key numbers
- Share price
- ₹1,135.85
- Market cap
- ₹2,527 Cr
- Revenue (annual)
- ₹251.7 Cr
- Net profit (annual)
- ₹30.48 Cr
- P/E (TTM)
- 70.0×Sector 50.4×
- Promoter holding
- 52.52%-0.34% QoQ
- FII holding
- 12.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sakar Healthcare Ltd
All →Sakar Healthcare Other Announcement
Sakar Healthcare Limited appointed M/s. Kashyap R. Mehta & Partners as the company's Secretarial Auditors for a five-year term, effective September 22, 2026, following shareholder approval at the AGM.
Sakar Healthcare Annual General Meeting
Sakar Healthcare's 22nd AGM was held on September 22, 2026, adopting audited financials and re-appointing a director. Routine resolutions were passed including secretarial auditor appointment.
Sakar Healthcare Earnings Call Transcript: Key Takeaways
Sakar Healthcare Q1 FY27 results show strong oncology pivot with 38% YoY revenue growth and 120% profit jump.
- Call
- Guides 100% growth
Sakar Healthcare Q1 FY27 Results: Net Profit ₹10.3 Cr, Up 119.1% YoY
Sakar Healthcare Ltd reported revenue from operations of ₹73 Cr (+38.5% YoY) and net profit of ₹10.3 Cr (+119.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹10.3 Cr · +119.1% YoY
Sakar Healthcare Earnings Call: Key Takeaways
Sakar Healthcare Q4 FY26 revenue grew 42% YoY to ₹71.1cr with 37% EBITDA margins. Strategy focuses on transforming into a pure-play oncology exporter via its EU GMP facility.
Sakar Healthcare Earnings Call: Key Takeaways
Sakar Healthcare Q4FY26 presentation highlights a strategic shift toward high-margin oncology, leveraging a new EU-GMP integrated API-FDF facility in Bavla to drive specialized global healthcare solutions.